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CRTh2 chemoattractant receptor-homologous molecule expressed on T-helper type 2; 
PGD2 prostaglandin D2;  
CHO, Chinese hamster ovary; 
HBSS, Hanks Balanced Salt Solution; 
QAW039, 2-(2-methyl-1-1(4-(methylsulphonyl)-2-(trifluromethyl)benzyl)-1H-pyrrolo[2,3-
b]pyridine-3-yl)acetic acid (fevipiprant);  
NSB, non-specific binding; 
CPM, counts per minute; 
WBSC, whole blood shape change; 
ISC, isolated cellular shape change; 
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Abstract 
Here we describe the pharmacological properties of a series of clinically relevant 
chemoattractant receptor-homologous molecule expressed on T-helper type 2 (CRTh2) 
receptor antagonists including fevipiprant (NVP-QAW039 or QAW039) which is currently in 
development for treatment of allergic diseases. [3H]-QAW039 displayed high affinity for the 
human CRTh2 receptor (1.14 ± 0.44 nM) expressed in CHO-cells, the binding being 
reversible and competitive with the native agonist prostaglandin D2 (PGD2).   The binding 
kinetics of QAW039 determined directly using [3H]-QAW039 revealed mean kinetic kon and 
koff values for QAW039 of 4.5x10
7 M-1min-1 and 0.048 min-1 respectively.  Importantly, the 
kinetic off-rate (koff) of QAW039 (t1/2 = 14.4 min) was >7 fold slower than the slowest 
reference compound tested AZD-1981. In functional studies QAW039 behaved as an 
insurmountable antagonist of PGD2 stimulated [
35S]-GTPS activation and its effects were 
not fully reversed by increasing concentrations of PGD2 following an initial 15min incubation 
period. This behaviour is consistent with its relatively slow dissociation from the human 
CRTh2 receptor.  In contrast the inhibitory effect of the other ligands tested was fully 
reversed by the 15min time point, whereas QAW039’s effects persisted for >180min.  All 
CRTh2 antagonists tested inhibited PGD2 stimulated human eosinophil shape change but 
importantly QAW039 retained its potency in the whole blood shape change assay relative to 
the isolated shape change assay, potentially reflective of its relatively slower off-rate from the 
CRTh2 receptor. QAW039 was also a potent inhibitor of PGD2 induced cytokine release in 
human Th2 cells. Slow CRTh2 antagonist dissociation could provide increased receptor 
coverage in the face of pathological PGD2 concentrations, which may be clinically relevant. 
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Introduction 
The chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells 
(CRTh2) is a class A G protein-coupled receptor involved in the modulation of inflammatory 
responses.  CRTh2 (or DP2) is also expressed on innate immune cells such as eosinophils, 
basophils (Nagata et al., 1999a and 1999b) and group 2 lymphoid cells (ILC2) (Xue et al., 
2014) and is known to play a role in the pathophysiology of airway disease.   
Activation of CRTh2 receptors occurs via the natural ligand prostaglandin D2 (PGD2), a 
major product of the cyclooxygenase pathway released primarily by allergen activated mast 
cells (Miadonna et al., 1990) in asthmatic and allergic rhinitis patients.  High levels of PGD2 
(Murray et al., 1986; Wenzel et al., 1989; Crea et al., 1992; Nowark et al., 1993; Horlak et al., 
1998) lead to recruitment and activation of Th2-cells and stimulate eosinophil shape change 
and migration (Pettipher et al., 2007). PGD2 also promotes increased CD11b expression, 
which facilitates cell adhesion on the vascular cell wall and movement of eosinophils from 
the circulation to the site of inflammation (Monneret et al., 2001; Gyles et al., 2006).  More 
recently it has been reported that patients with severe asthma accumulate a particular subtype 
of PGD2-producing mast cells in the airway submucosa and epithelium resulting in increased 
sputum levels of PGD2 relative to other steroid treated asthma patients (Balzar et al., 2011).   
Stimulation of CRTh2 receptors found in the bronchial epithelium has been shown to drive 
epithelial differentiation, suggesting that in addition to its well-characterized role in 
inflammatory cell migration, CRTh2 may contribute to airway remodeling in asthmatic 
patients (Stinson et al., 2015). Preclinical studies suggest that CRTh2 antagonism may also 
potentially accelerate apoptosis and clearance of Th2-cells from inflamed tissue, thereby 
promoting the resolution of the underlying inflammation in allergic asthma and other related 
conditions such as allergic rhinitis (Xue et al., 2009).  In animal models of acute allergen 
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challenge PGD2 mediated effects are blocked by CRTh2 antagonists acting on CRTh2 
receptors on Th2-cells and inflammatory effector cells downstream of the allergic cascade 
(Uller et al., 2007).  Multiple selective orally available antagonists have been since described 
in the literature with compounds such as setipiprant (Diamant et al., 2014), BI-671800 (Krug 
et al., 2014) and OC-459 (Barnes et al., 2012) providing clinical proof of concept in asthma 
and allergic rhinitis.  A comprehensive review of the current status of these and other 
compounds including the dual CRTh2/thromboxane A2 receptor (TP) antagonist ramatroban 
is available (Norman 2014). 
Drug-receptor interactions are traditionally characterised in terms of potency and efficacy in 
preclinical screening programs.  However increasing evidence suggests that the time 
molecules reside at their cellular target can provide an important indicator of their clinical 
performance (Swinney 2009). In functional assays these slowly dissociating compounds 
exhibit the well documented phenomenon of ‘hemi-equilibrium’ (Charlton & Vauquelin 
2010), characterised functionally as a depressed agonist response and one which can 
potentially aid the selection of molecules for further pre-clinical development.  For these 
reasons we employed the [35S]-GTPS assay format to assess the ability of CRTh2 
antagonists to inhibit PGD2 responses over time. 
We recently reported the discovery of QAV680, a potent/selective CRTh2 receptor 
antagonist, suitable for clinical testing in allergic diseases (Sandham et al., 2013).  QAV680 
dosed twice or four times daily was shown to reduce nasal symptom scores following 
allergen challenge in patients with allergic rhinitis (Erpenbeck et al., 2014a, 2014b).  A 
follow-up compound was consequently sought with improved duration of action (DOA) 
giving the potential for once daily dosing in order to increase patient compliance.  This 
optimization resulted in the discovery of 2-(2-methyl-1-1(4-(methylsulphonyl)-2-
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(trifluromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridine-3-yl)acetic acid (QAW039, fevipiprant), 
which is currently in clinical development for asthma and atopic dermatitis. 
Previous work has demonstrated different modes of action (MoA) of antagonists of CRTh2 
receptors for example studies have suggested a non-competitive MoA for the small molecule 
antagonist AZD-1981 (Schmidt et al., 2013) whilst structurally similar compounds such as 
OC-459 and ramatroban have been shown to be competitive (Pettipher et al, 2012; Uller et 
al., 2007; Mathiesen et al., 2006). A complicating factor/explanation could be the 
phenomenon of hemi-equilibrium resulting from slow dissociation which leads to 
insurmountable antagonism under certain conditions and can be inadvertently mistaken for 
non-competitive inhibition.  The aim of the present study was to determine the binding 
characteristics of QAW039 and a cohort of clinically relevant reference antagonists at the 
human CRTh2 receptor and to explore the influence of kinetics on compound MoA by 
investigating the effect of these ligands on PGD2 stimulated CRTh2 responses in both 
recombinant and relevant inflammatory cell types. 
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Materials and Methods 
Cell culture and membrane preparation 
CHO-cells expressing the human CRTh2 receptor were grown to 80-90% confluence in 500 
cm2 cell-culture plates at 37oC in 5% CO2. All subsequent steps were conducted at 4C to 
avoid receptor degradation. The cell-culture media was removed and ice cold HBS-EDTA 
(1x 10 mL; 10 mM HEPES, 0.9% w/v NaCl, 0.2% w/v EDTA pH 7.4) was added to the cells 
which were then scraped from the plates into a 50 mL Corning tube and subsequently 
centrifuged at 250 xg for 5 min to allow a pellet to form. The supernatant fraction was 
aspirated and 10 mL per 500 cm2 tray of wash buffer (10 mM HEPES, 10 mM EDTA, pH 
7.4) was added to the pellet. This was homogenized using an electrical homogenizer ‘ultra-
turrax’ (position 6, 4x 5 second bursts) and subsequently centrifuged at 48,000 xg at 4C 
(Beckman Avanti J-251 Ultracentrifuge) for 30 min.  The supernatant was discarded and the 
pellet re-homogenized and centrifuged as described above, in wash buffer. The final pellet 
was suspended in ice cold 10 mM HEPES, 0.1 mM EDTA, pH 7.4 at a concentration of 5-10 
mg mL-1. Protein concentration was determined by the Bio-Rad Protein Assay based on the 
method of Bradford (1976), using BSA as a standard. Membrane aliquots were maintained at 
-80C until required. 
Compounds 
QAW039 was prepared using procedures reported for QAV680 (Sandham et al., 2013) and 
all reference CRTh2 antagonists were prepared according to patent procedures referenced in 
Lamers et al., (2013). The preparation of [3H]-QAW039 has been previously described, see Luu 
et al., (2015). [3H]-OC-459 was prepared by direct hydrogen isotope exchange on solid support, 
further details plus the structures, specific activity and chemical purity of both radioligands are 
provided in the Supplemental Methods. 
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Common procedures applying to [3H]-QAW039 and [3H]-OC-459 radioligand binding 
experiments 
All radioligand experiments were conducted in 96 deep-well plates in assay binding buffer 
(HBSS containing 10 mM HEPES, 1% DMSO and 0.02% pluronic acid pH 7.4) at 37oC.  In 
all cases non-specific binding (NSB) was determined in the presence of 3 M AZD-1981 a 
selective CRTh2 antagonist. After the indicated incubation period, bound and free 
radioligand were separated by rapid vacuum filtration using a FilterMateTM Cell Harvester 
(Perkin Elmer, Beaconsfield, U.K.) onto 96-well GF/B filter plates pre-treated with assay 
buffer and rapidly washed three times with ice cold wash buffer 20 mM HEPES containing 1 
mM MgCl2 pH 7.4. After drying (> 4 h) 40 L of MicroscintTM 20 (Perkin Elmer, 
Beaconsfield, U.K.) was added to each well and radioactivity quantified using single photon 
counting on a TopCountTM microplate scintillation counter (Perkin Elmer, Beaconsfield, 
U.K.) Aliquots of [3H]-QAW039 and [3H]-OC-459 were also quantified accurately to 
determine how much radioactivity was added to each well using liquid scintillation 
spectrometry on a Hidex 300SL scintillation counter (LabLogic, Sheffield, U.K.). In all 
experiments total binding never exceeded more than 10% of that added and therefore limiting 
significant depletion of the free radioligand concentration (Carter et al., 2007). To ensure the 
experiment was at the described temperature all components were pre-warmed for > 2 hours. 
[3H]-QAW039 and [3H]-OC-459 saturation binding 
Binding was performed with a range of concentrations of [3H]-QAW039 and [3H]-OC-459 to 
construct saturation binding curves, as described by Sykes et al., (2010). CHO-CRTh2 cell-
membranes (0.5 g well-1 respectively) were incubated in 96-deep well plates at 37°C in 
assay binding buffer with gentle agitation for 3 hour, to ensure equilibrium was reached. Due 
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to the low concentrations of [3H]-QAW039 employed, the assay volume was increased to 1.5 
mL to avoid significant depletion of the radioligand and unlabelled competitors. 
[3H]-QAW039 competition binding 
To obtain affinity estimates for unlabeled QAW039 and the other unlabeled CRTh2 reference 
compounds, [3H]-QAW039 displacement experiments were performed in a total reaction 
volume of 0.5 ml. [3H]-QAW039 was used at a concentration of approximately 1 nM such 
that the calculated total binding never exceeded more than 10% of that added and therefore 
avoided ligand depletion.  [3H]-QAW039 was incubated in the presence of the indicated 
concentration of unlabeled CRTh2 antagonist and CHO-cell membranes expressing the 
CRTh2 receptor (0.5 g well-1 respectively) at 37°C in assay binding buffer containing 
GTPS (30M) in 96-deep well plates with gentle agitation for 2.5 hour to ensure equilibrium 
was reached.  In a separate study designed to assess the mode of action (MoA) of QAW039 
increasing concentrations of [3H]-QAW039 (0.5, 1, 3, 10, 30 x Kd) were incubated against 
increasing concentrations of unlabeled QAW039 (homologous binding) and increasing 
concentrations of the native agonist PGD2 plus selected CRTh2 antagonists all in the 
presence of GTPS (30M). 
Determination of the binding kinetics of [3H]-QAW039 at human CRTh2 receptors 
To accurately determine the kon and koff, and the observed rate of association (kob) was 
calculated with at least three different concentrations of [3H]-QAW039 (0.3, 1 and 3 x Ki). 
The appropriate concentration of [3H]-QAW039 was incubated with CRTh2 CHO-cell 
membranes (0.5 g well-1) in assay binding buffer with gentle agitation (final assay volume 
500 L). The binding of [3H]-QAW039 to the CRTh2 receptor was initiated with the addition 
of CHO-cell membranes and bound and free [3H]-QAW039 were separated at the indicated 
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time-points to construct association kinetic curves. Care was taken to ensure that equilibrium 
was reached for each concentration, before the experiment was terminated. After incubation, 
bound was separated from free by rapid filtration, plates were left to dry and radioactivity 
quantified (all as previously described). 
Determination of the dissociation rate (koff) of [3H]-QAW039 and [3H]-OC-459 at the 
human CRTh2 receptor 
A single concentration of [3H]-QAW039 (2.5 nM) and [3H]-OC-459 (5 nM) was allowed to 
fully associate with human CRTh2 CHO-cell membranes (0.5 g well-1) in a final reaction 
volume of 500 L. To construct dissociation kinetic curves an excess of AZD1981 (3 M) 
was added at various time intervals to the reaction mixture to initiate dissociation of the 
radioligands. Dissociation was monitored for up to 150 min until [3H]-QAW039 was fully 
dissociated from the human CRTh2 receptor. Bound and free [3H]-QAW039 and [3H]-OC-
459 were separated at the indicated time-points by rapid filtration, plates were left to dry and 
radioactivity quantified (all as previously described). 
Competition kinetics at human CRTh2 receptors 
The kinetic parameters of unlabeled QAW039 and the other CRTh2 antagonists were 
assessed using the methodology of Sykes et al., (2010). An experimentally calculated 
concentration of [3H]-QAW039 (2.5 nM, a concentration which avoided ligand depletion in 
this assay volume) was incubated with the indicated concentration(s) of unlabeled competitor 
in a final volume of assay binding buffer of 500 L. Each time-point was conducted on the 
same 96 deep-well plate incubated with constant gentle agitation. The experiment was 
initiated by the addition of CRTh2 CHO-cell membranes (0.5 g well-1) containing GTPS 
(30M) and the plates harvested (as previously described) at the indicated time-points. 
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[35S]-GTPS functional binding assay 
A range of concentrations of test compound were prepared in 100% DMSO and 2.5 µL added 
to a 96-well white OptiPlate. To each well 200 µL of assay buffer (20 mM HEPES, 10 mM 
MgCl2, 100 mM NaCl and 1 mM EDTA) containing 0.1% HSA, 30 μg mL-1 saponin (added 
fresh on the day of experimentation), 50 μg mL-1 CHO-CRTh2 membranes, 3.7 μM 
guanosine 5’-diphosphate sodium salt (GDP), 2.5 mg mL-1 WGA PVT SPA beads and 50 μL 
of [35S]-Guanosine 5'-(γ-thio)triphosphate ([35S]-GTPγS) at a concentration of 300 pM was 
added and incubated at room temperature with gentle agitation for 2 hr. Following this 
incubation 2.5 µL of increasing concentrations of PGD2 prepared at 100x concentration in 
100% DMSO was added and incubated at room temperature with gentle agitation for 15, 60 
and 180 min. Eleven concentrations of PGD2 were studied in total.  Following this the plates 
were centrifuged for 3 min at 1000 g and bound [35S]-GTPγS quantified using single photon 
counting on a TopCountTM microplate scintillation counter (Perkin Elmer, Beaconsfield, 
UK). 
Isolated eosinophil shape change assay 
Granulocytes were isolated from the blood of healthy normal volunteers. The granulocytes 
were incubated with PGD2 for 5 min at 37 
oC. The reaction was terminated by addition of 
CellFixTM and data was acquired on FACSCalibur flow cytometer, first with FSC/SSC plots 
and then FSC/FL-2 to distinguish eosinophils from neutrophils. Data were fitted to a 
sigmoidal curve (Origin 7 or XL fit) to give a typical EC50 for PGD2 of 0.72 ± 0.11 nM (n = 
3, data not shown). Antagonist curves were determined as follows: aliquots of granulocyte in 
assay buffer containing 1% DMSO were treated with aliquots of 10 increasing test compound 
concentrations and the mixture incubated for 5 min at 37 oC. Agonist (EC70 concentration) 
was added and the mixture was incubated for a further 5 min. The reaction was terminated 
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and activity measured as above. Data were fitted to a sigmoidal curve (Origin 7 or XL Fit) to 
give an IC50 value. 
Whole blood eosinophil shape change assay 
Blood was collected into sterile 3.8% (w/v) trisodium citrate from healthy atopic volunteers 
and used immediately with minimum disturbance. Agonist curves were determined as 
follows: aliquots of whole blood (80 L) were incubated in assay buffer containing 1% 
DMSO for 5 min at 37 oC. Increasing concentrations of PGD2 were added and the mixture 
was incubated with gentle shaking at 37 oC for 5 min. The reaction was terminated by 
addition of ice cold CellFixTM (250 L), followed by ammonium chloride lysis solution (1.5 
ml). After incubation on ice for 40–60 min, data was acquired on FACSCalibur flow 
cytometer, first with FSC/SSC plots and then FSC/FL-2 to distinguish eosinophils from 
neutrophils. Data were fitted to a sigmoidal curve (Origin 7 or XL fit) to give a typical EC50 
for PGD2 of 0.94 ± 0.18 nM (n = 3, data not shown).  Antagonist curves were determined as 
follows: aliquots of whole blood (80 L) and test compound (10 concentrations) were 
incubated in assay buffer containing 1% DMSO for 5 min at 37 oC. Agonist (EC70 
concentration in 10 L in assay buffer) was added and the mixture incubated with gentle 
shaking at 37 oC for 5 min. The reaction was terminated and samples measured as described 
above. 
Th2 cell cytokine release assay 
CRTh2+ Th2 cells isolated by either MACS or MoFlo (see Supplemental methods) were 
counted and seeded in flat-bottom 96 well plates at a concentration of 100,000 cells per well. 
Cells were seeded in X-VIVO 15 medium plus 10 % human AB serum and 1 % 
Penicillin/Streptomycin. QAW039 (10 mM stock solution in 100 % DMSO) was applied to 
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the cells (10 μL of a 10x final concentration) at a range of concentrations between 1000 nM – 
0.3 nM and incubated with the cells (37˚C, 5% CO2) for 30 minutes prior to PGD2 being 
added. PGD2 was added to the cells at a final concentration of 200 nM (10 μL of a 10x 
solution – stock made up in 100% ethanol). Unstimulated cells were included in the assay - 
cells treated with medium alone; and PGD2 at 200 nM ± vehicle (0.01 % DMSO) was also 
included as a control. Once all additions had been made, the plate was incubated for a further 
6 hours at 37˚C, 5 % CO2 after which the plate was centrifuged at 400 xg for 10 minutes and 
the supernatant was harvested into 96-well plates and stored at -20˚C prior to cytokine 
analysis was carried out. The supernatant samples were analysed for levels of the Th2 
cytokines IL-13, IL-5 and IL-4, and also IL-12 (as a negative control) using the Mesoscale 
Discovery (MSD) human IL-13 issue culture assay kit plus detection antibodies for human 
IL-4, IL-5 and IL-12 (total). Briefly, 25 μL of each Calibrator (standard) at a range of 10,000 
– 2.4 pg/mL was applied to the plate in duplicate and 25 μL of neat test sample in triplicate. 
The plate was then incubated at RT for 2 hours with shaking at 800 rpm. 25 μL of the 
Detection Antibody solution mix (each antibody diluted 1 in 50 in antibody dilution buffer) 
was then added to each well and incubated for a further 2 hours at RT with shaking at 800 
rpm. The plate was then washed 3 times in PBS + 0.05 % Tween-20 and 150 μL of 2x Read 
Buffer T was added to each well. The plate was analysed on the SECTOR™ Imager and the 
results for each cytokine were analysed using Discovery Workbench software. IC50 values 
were calculated using GraphPad Prism v4.0 software. 
Interpretation of data 
Data analysis 
As the amount of radioactivity varied slightly for each experiment (< 5%), data are shown 
graphically as the mean ± s.d. for individual representative experiments, whereas all values 
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reported in the text and tables are mean ± s.e. mean for the indicated number of experiments. 
All experiments were analyzed by non-regression using Prism 6.0 (GraphPad Software, San 
Diego, U.S.A.). Competition displacement binding data were fitted to sigmoidal (variable 
slope) curves using a “four parameter logistic equation”: 
 fficientX).Hillcoe(logEC50101 / Bottom)(TopBottomY   
IC50 values obtained from the inhibition curves were converted to Ki values using the method 
of Cheng and Prusoff (1973).  [3H]-QAW039 association data was fitted as follows to a 
global fitting model using GraphPad Prism 6.0 to simultaneously calculate kon and koff using 
the following equation where kob equals the observed rate of association: 
offonob kkk    d]Radioligan[  
Association and dissociation rates for unlabeled antagonists were calculated using the 
equations described by Motulsky and Mahan (1984): 
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Where: X = Time (min), Y = Specific binding (CPM), k1 = kon [
3H]-QAW039, k2 = koff [
3H]-
QAW039, L = Concentration of [3H]- QAW039 used (nM), Bmax = Total binding (CPM), I = 
Concentration unlabeled antagonist (nM).  
Fixing the above parameters allowed the following to be calculated: k3 = Association rate of 
unlabeled ligand (M-1 min-1), k4 = Dissociation rate of unlabeled ligand (min
-1). 
Dissociation of [3H]-QAW039 and [3H]-OC-459 was fitted to a one phase mono-exponential 
decay function to estimate the dissociation rate of QAW039 directly. 
PGD2 stimulated [
35S]-GTPγS binding data were fitted to sigmoidal (variable slope) curves 
using the four-parameter logistic equation described above.  pA2 values were estimated 
directly from Schild analysis following normalisation of data to the control maximal response 
(see supplemental Figure 3 and supplemental Table 1).  Specifically data were fitted to a 
using a four-parameter logistic equation in Prism 6.0 as described above (each curve was fit 
to its own value of n, EC50, bottom (Emin) and top (Emax)) and to a simpler model (where a 
common Emin, Emax and n values were used).  When the F-statistic indicated that a 
significantly better fit was obtained with the simple model, dose ratios (DR) were calculated 
for construction of Schild plots.  Data were then fitted to the Gaddum/Schild equation in 
Prism 6.0 to obtain an estimation of the Schild slope.  If the Schild slope did not differ 
significantly from unity (F-test) the data was refit to a slope of 1.0 to derive pA2 values.   
Corrected pA2 estimates were derived by correcting for % bound to HSA (0.1%) using the 
method of Toutain and Bousquet-Melou (2002).  The validity of this correction is borne out 
of the fact that plasma protein binding (see Table 3) and HSA binding are directly correlated 
for the CRTh2 antagonists tested in this study (P<0.0001, r2 = 0.97 data not shown).   For a 
full explanation of this conversion and the effects of protein on apparent receptor affinity see 
Blakeley et al., 2015.  PGD2 did not reach equilibrium with QAW039 in the time frame of the 
GTPS assay so EC30 estimates were taken from which we were able to estimate log DR-1 
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values to derive a Schild plot and obtain a pA2 value.  Estimated pA2 values along with 
corrected estimated pA2 estimates are shown in supplemental Table 1. 
Functional GTPS data for QAW039 were fitted according to a combined operational and 
hemi-equilibrium model for competitive antagonism under non-equilibrium conditions 
(Kenakin, 2009; Mould et al., 2014; Riddy et al., 2015) in order to derive kinetic parameters 
for QAW039. 
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where [A] and [B] represent the concentrations of PGD2 and QAW039, respectively, KA and 
KB represent the respective equilibrium dissociation constants, koff is the dissociation rate 
constant for the antagonist (min−1), t is the assay incubation time (min), τ is the operational 
efficacy of PGD2 and Em is the maximal system response. All parameters were shared across 
all data sets except t which were fixed to the assay incubation time. In all cases, potency and 
affinity values were estimated as logarithms (Christopoulos, 1998). Data shown are the mean 
± SEM (see supplemental Figure 4). 
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Results 
QAW039 and related CRTh2 compounds 
The structure of QAW039 and related CRTh2 antagonists and the agonist indomethacin are 
shown in Figure 1.  QAW039 is a triﬂuoromethyl derivative of the previously described 7-
azaindole-3-acetic acid QAV680 (Sandham et al., 2013).  The measured lipophilicity 
(logD7.4) of these compounds is lower than other described CRTh2 antagonists (see Table 3) 
which likely contributes to their lower plasma protein binding. 
Characterisation of CHO-CRTh2 expressing cell line. 
Specific [3H]-QAW039 and [3H]-OC-459 binding to human CRTh2 receptors in CHO 
membranes was saturable and best described by the interaction of the radioligand with a 
single population of high affinity sites. A representative saturation binding curve for [3H]-
QAW039 and [3H]-OC-459 binding to the human CHO-CRTh2 receptor is shown in Figure 
2A and B. The expression level of the CHO-CRTh2 in the CHO-cell line, and the 
corresponding equilibrium dissociation constant (Kd) of [
3H]-QAW039 and [3H]-OC-459 
determined from [3H]-QAW039 saturation binding studies are shown in Table 1. 
Determination of the dissociation rate (koff) of [3H]-QAW039 and [3H]-OC-459 at the 
human CRTh2 receptor 
A single concentration of [3H]-QAW039 (2.5 nM) and [3H]-OC-459 (5 nM) was allowed to 
fully associate with the human CRTh2 receptor. An excess of AZD-1981 (3 M) was then 
added to the reaction mixture to initiate dissociation of [3H]-QAW039 and [3H]-OC-459. 
Dissociation was monitored until [3H]-QAW039 and [3H]-OC-459 was fully dissociated from 
the human CRTh2 receptor (see Figure 1C and D). The data was fitted to a mono exponential 
MOL# 101832 
19 
 
decay function to estimate a koff value for QAW039 and OC-459 directly. A koff value of 
0.050 ± 0.006 min-1 (t1/2 = 14.2 min) was determined for the slowly dissociating [
3H]-
QAW039 and a value of 2.80 ± 0.53 min-1 (t1/2 = 0.28 min) for the more rapidly dissociating 
[3H]-OC-459 binding to human CRTh2 receptors. 
Determination of the equilibrium binding affinity constant of CRTh2 antagonists and 
agonists at CRTh2 receptors. 
IC50 values determined from competition binding experiments were converted to equilibrium 
binding constants (pKi) by using the equation of Cheng and Prusoff (1973) and using the Kd 
values of [3H]-QAW039 as described in the methods section. The competition binding curves 
showing displacement of [3H]-QAW039 by QAW039 and the other CRTh2 compounds 
tested is shown in Figure 3A and B, affinity values (pKi) for CRTh2 antagonist and agonist 
binding to human CRTh2 receptors are summarized in Table 2.   
Determination of the kinetic parameters of [3H]-QAW039 at the human CRTh2 receptor 
In order to calculate the kinetic on (kon) and off-rates (koff) of the unlabeled QAW039 and the 
other CRTh2 antagonists the kinetic parameters of the radioligand, [3H]-QAW039 were first 
determined.  A family of association kinetic curves was constructed using a range of [3H]-
QAW039 concentrations. Each association curve was monitored until equilibrium so that 
Ymax was reached (see Figure 4A). From this type of analysis it is possible to estimate both 
kon and koff values for QAW039 by fitting the data to a global kinetic model. A kon value for 
[3H]-QAW039 of 4.52 ± 0.45x107 M-1 min-1 and a koff value of 0.048 ± 0.005 min was 
determined. From the koff value a t1/2 of dissociation (0.693/koff) of 14.4 min was calculated 
for [3H]-QAW039. Kobs increased in a linear manner with [
3H]-QAW039 concentration (see 
Figure 4B) and the mean kinetic parameters estimated from these plots were in good 
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agreement with the values estimated from the global fit described above (linear fit mean koff = 
0.044 ± 0.004 and kon = 4.86 ± 0.53 x10
7 M-1 min-1). 
Determination of the kinetic parameters of QAW039 and competitor compounds at human 
CRTh2 receptors. 
Using the equations described in methods section and the kinetic values obtained for [3H]-
QAW039 as detailed above, the association and dissociation rates for unlabeled QAW039, 
OC-459 and the other CRTh2 antagonists for the human CRTh2 (see Table 2 and Figures 4C-
D and supplemental Figure 1A-E respectively) receptor were calculated.  The kinetic on (kon) 
and off-rates (koff) determined for QAW039 using the Motulsky-Mahan methodology were 
not significantly different from the values calculated from the global kinetic analysis 
suggesting that [3H]-QAW039 is suitable for the determination of kinetic parameters of 
unlabeled CRTh2 antagonists.  To validate the rate constants, the kinetically derived 
dissociation constant (Kd) values (koff/kon) were compared with the dissociation constant (Ki) 
obtained from equilibrium competition binding experiments. There was a very good 
correlation (r2 = 0.95, P < 0.001, data not shown) between these two values, indicating the 
kinetic parameters were accurate. 
QAW039 is a competitive antagonist of the native CRTh2 receptor agonist PGD2. 
In order to explore the nature of the interaction of QAW039 with the CRTh2 receptor we 
employed the technique of competitive binding.  Using this technique we have explored the 
inhibitory potency of unlabelled QAW039, AZD-1981, OC-459 and the native agonist PGD2 
over a range of concentrations of [3H]-QAW039 designed to saturate the receptor.  At the 
lowest radioligand concentration employed, ~0.3 nM, the pIC50 value for displacement by 
QAW039 itself was 9.05 ± 0.10 (see Figure 5A). As expected a linear increase in the pIC50 
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value was obtained as the radioligand concentration was increased to the maximum 
concentration employed in the study, ~30nM (~30-fold greater than Kd from saturation 
binding) (see Figure 5E).  This same pattern of behaviour was mimicked by the other 
structurally related CRTh2 antagonists, and PGD2 which were investigated in parallel.  The 
difference in pIC50 values for unlabelled PGD2 were precisely in line with those predicted by 
the Cheng–Prusoff relationship (Cheng and Prusoff, 1973), using the Kd value for QAW039 
obtained from saturation binding, see Table 1), suggesting that unlabelled PGD2 displaced the 
radioligand competitively. 
Determination of the effect CRTh2 antagonists on PGD2 stimulated [35S]-GTPS binding 
to human CRTh2 receptors. 
To investigate the potential for QAW039 and the other CRTh2 antagonists to display 
insurmountable behavior in a [35S]-GTPS binding assay, PGD2 concentration response 
curves were constructed in the presence of increasing concentrations of pre-equilibrated 
antagonist, see Figure 6.   [35S]-GTPS binding to CHO-hCRTh2 membranes was measured 
at different time intervals following incubation with the endogenous CRTh2 agonist PGD2.  
QAW039 produced a clear reduction in the Emax of PGD2 stimulated GTPS binding 
following a 15 min incubation period with PGD2 (Figure 6A) demonstrating its ability to 
produce insurmountable antagonism in a functionally relevant second messenger reporter 
assay. The incubation was extended to 180 min to allow the PGD2 to reach equilibrium with 
the receptor and fully activate a second messenger response. The inhibitory effect of 
QAW039 was readily reversible with time, however the inhibitory effects of QAW039 were 
not fully reversed even following a 180 min incubation period with PGD2 (see supplemental 
Figure 3).   Also apparent was a reduction in the basal accumulation of GTPS binding in the 
presence of increasing concentrations of QAW039 and the other CRTh2 antagonists (see 
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Figure 6A-G).  This demonstrates that these compounds behave as inverse agonists of CRTh2 
mediated GTPS accumulation.  In contrast to QAW039, the more rapidly dissociating 
CRTh2 antagonists tested did not produce any noticeable depression of the PGD2 maximal 
response following a 15 min incubation (see Figure 6B-G).  PGD2 stimulated [
35S]-GTPS 
binding in the presence of these more rapidly dissociating CRTh2 compounds following a 
180 min incubation period are shown for comparison with QAW039, see supplemental 
Figure 3B-G respectively. 
It is not possible to accurately derive pKB values directly from the GTPS binding 
experiments since the compounds are bound to plasma proteins (eg HSA, see Table 3) 
resulting in irregular shifts of the PGD2 concentration response curves at concentrations of 
compound which come close to saturating the protein (0.1% HSA or 15 M) present in the 
assay buffer.   Once HSA gradually becomes saturated by the increasing concentrations of 
antagonist the Schild slopes become gradually steeper as more antagonist becomes free in 
solution and available to bind the CRTh2 receptor (i.e. deviation from constant % bound, see 
Blakeley et al., 2015).   As would be predicted this effect is most pronounced for the low 
CRTh2 affinity, highly protein bound compound setipiprant (see supplemental Figure 3G).  
However Schild plots of the lower concentrations of QAW039, QAV680, AZD-1981, OC-
459, BI-671800 and ramatroban (<10M, i.e. below the saturating protein concentration) 
tested resulted in Schild slopes not significantly different from 1.0 and pA2 values and in line 
with expected pKi estimates following correction for HSA binding further suggesting that 
these compounds are behaving competitively with PGD2 (see supplemental Figure 3, Table 2 
and supplemental Table 1).  Although PGD2 did not fully reach equilibrium with QAW039 in 
the 180 min time frame of the GTPS assay, we previously determined it to be competitive 
with PGD2 based on competitive binding data, hence we have estimated DR-1 values to 
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derive a Schild plot and obtain an estimated PA2 value.  Thus the [35S]-GTPS competition 
assay data is entirely consistent with the radioligand competition binding analysis and suggest 
that these molecules interact with the same orthosteric binding pocket as PGD2. 
When a comparison of CRTh2 antagonist inhibitory potency was made at the 15min time 
point in the [35S]-GTPS assay, following addition of a maximally effective concentration of 
PGD2 (1M), the superior potency of QAW039 compared to the other CRTh2 compounds 
tested in this study was clearly visible (see Figure 7).  This suggests that kinetic off-rate could 
potentially play a role in driving the superior potency of this compound.  
The effect of time on the potency of CRTh2 antagonists to inhibit PGD2 (1M) stimulated 
GTPS accumulation is shown in Figure 8.  QAW039 is >10-fold more effective at inhibiting 
the PGD2 response following a 15min incubation compared to the full 180min incubation 
period (Figure 8A). This reflects its very slow dissociation from the CRTh2 receptor in the 
face of high concentrations of PGD2.  The other CRTh2 antagonist examined are equi-
effective at all-time points demonstrating that kinetics does not play any role in determining 
their potency under these experimental conditions (Figure 8B-G). 
An estimate of the affinity and dissociation rate of the CRTh2 antagonist QAW039 from 
functional [35S]-GTPS data following a 60 min incubation was obtained by fitting data 
according to an operational hemi-equilibrium model for competitive antagonism first 
described by Kenakin (2009) and recently employed practically to estimate the dissociation 
rates of orexin-2 antagonists and muscarinic M1 antagonists in functional assays (Mould et 
al., 2014; Riddy et al., 2015), see supplemental Figure 4 and supplemental Table 2. A pA2 
value for QAW039 of 3.2 ± 0.7 nM was estimated which is very much in line with affinity 
estimates obtained from kinetic association experiments performed at room temperature (Kd 
1.39 ± 0.23 nM, see supplemental Figure 5 and supplemental Table 3) and the pA2 obtained 
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from the Schild analysis (see supplemental Table 1).  Importantly the koff value for QAW039 
of 0.005min-1 was also within 3-fold of that estimated in kinetic association binding 
experiments performed at room temperature (QAW039 koff = 0.012 ± 0.001 see supplemental 
Figure 5 and supplemental Table 3) demonstrating the potential for the GTPS assay to 
identify very slowly dissociating compounds.  In contrast it was not possible to fit other 
ligands to the operational hemi-equilibrium model as their effects were fully reversible within 
the 15min incubation period. Confirmation that [3H]-OC-459 was relatively rapidly 
dissociating when profiled at room temperature comes from kinetic association binding 
experiments see supplemental Figure 5 and supplemental Table 3. 
Determination of the effect of QAW039 on PGD2 stimulated whole blood eosinophil shape 
change.  
Migration of eosinophils from the microcirculation into sites of inflammation occurs as a 
consequence of cytoskeletal rearrangements in a process known as eosinophil shape change.  
Purified human eosinophils undergo shape change upon exposure to PGD2 in response to 
activation of CRTh2 and a similar response is seen in whole blood.  This study confirms the 
inhibitory effect of the tested CRTh2 antagonists in both the isolated and whole blood shape 
change assays.  QAW039 was the most potent compound tested at inhibiting PGD2 
stimulated eosinophil shape change, with comparable potencies in both the isolated and 
whole shape change assays (see Table 3).   
Determination of the effect of QAW039 on cytokine release from PGD2 stimulated CD4+ 
Th2 cells 
The chronic inflammatory response characteristically observed in allergic asthma occurs by 
the selective accumulation of Th2 lymphocytes which further potentiate the inflammatory 
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response by releasing Th2 cytokines such as IL-5 and IL-13.   The localized increase in the 
release of Th2 cytokines at the primary site of inflammation causes activation of Th2 cells, 
eosinophils and basophils. Here we show that QAW039 is a potent inhibitor of PGD2 induced 
release of IL-5 and IL-13 from human CD4+ Th2 lymphocytes (see Table 4). The potency of 
QAW039 in this cellular functional assay system is 15-20 fold greater than the previous lead 
compound QAV680.  
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Discussion 
It is potentially advantageous when developing antagonists of G protein coupled receptors to 
identify compounds which exhibit slow dissociation from the receptor (Tummino and 
Copeland 2008).  CRTh2 antagonists exhibiting such behavior may display greater clinical 
efficacy as a consequence of prolonged receptor blockade, which will effectively reduce the 
recruitment of proinflammatory eosinophils into existing areas of inflammation.  Such a 
profile could be particularly important in the asthmatic lung where local concentrations of 
PGD2 are likely to vary dependent on the numbers of activated mast cells, especially given 
that PGD2 release occurs in a matter of minutes after IgE activation (Kawata et al., 1995).  
Importantly, the transit time of ‘mixed leukocytes’ across the pulmonary circulation has very 
recently been quantified and is thought to be similar to that of neutrophils measured precisely 
at 14.2 seconds, only marginally slower than that reported for RBCs (Summers et al., 2014).  
This implies that sustained CRTh2 blockade will protect against eosinophil recruitment as 
they transit through areas of high PGD2 concentration in the lung.  Clinical data generated 
with QAW039 in eosinophilic asthmatics shows a reduction in both sputum and tissue 
bronchial biopsy eosinophils supporting this hypothesis (Berair et al., 2015). Prolonged 
CRTh2 receptor blockade therefore represents a new and potentially powerful approach for 
the treatment of allergic asthma. 
The binding properties of several clinically relevant CRTh2 antagonists including the 
recently developed QAW039 were determined at the human CRTh2 receptor in assay buffer 
containing physiological sodium ion concentration at 37oC.  Previous studies designed to 
assess the kinetics of unlabelled CRTh2 antagonists have employed non-physiological assay 
conditions, experiments being conducted at room temperature in the absence of salt (Gervais 
et al., 2011).  Findings from these early kinetic studies are therefore likely to overestimate the 
receptor target coverage since it has been well documented that compound kinetics is highly 
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dependent on temperature and sodium ion concentration (Sykes et al., 2012).  This 
phenomenon was also apparent in the current study with the off-rates of QAW039 and OC-
459 being up to 5-fold slower when measured at room temperature compared to 37oC. 
Other researchers have attempted to estimate dissociation t1/2s indirectly from functional 
[35S]-GTPS assays performed at room temperature by measuring responses to PGD2 (100 
M) at fixed time periods following a 60 min pre-incubation period with test compounds, 
allowing antagonist t1/2s to be estimated by fitting an exponential decay curve to the PGD2 
responses observed over time (Andrés et al., 2014). Although these results enabled a rank 
order of residence time to be established, the use of an accumulation assay mean the 
dissociation half-lives are again likely to be overestimated.  
In saturation binding experiments [3H]-QAW039 and [3H]-OC-459 display nM affinity for 
the human CRTh2 receptor expressed in CHO-cells.  The mean kinetic kon and koff values 
determined for [3H]-QAW039 were 4.5x107 M-1min-1 and 0.048min-1 respectively, producing 
a t1/2 value of 12 min and a kinetic Kd value of 1.06 ± 0.06 nM which is in excellent 
agreement with the equilibrium Kd value obtained in the saturation binding experiments 
described above.   In contrast, despite displaying comparable nM affinity, OC-459 was ~30x 
faster at dissociating from the CRTh2 receptor (t1/2 = 0.41 min).  To put this in context > 50% 
of OC-459 could potentially be displaced from the CRTh2 receptor in the time it takes for 
eosinophils to pass through the asthmatic lung, whereas in direct contrast <1.2% of QAW039 
will likely become displaced in the same time frame. 
The binding kinetics of unlabelled QAW039 and the other related CRTh2 antagonists 
including OC-459 were also determined indirectly using [3H]-QAW039 as the tracer through 
application of a competition binding model first described by Motulsky and Mahan (1984).   
The kinetic Kd values generated indirectly were in agreement with the Ki values generated by 
equilibrium competition kinetic binding validating the use of the current methodology. The 
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pharmacological properties of QAW039 are a significant improvement on those of our 
original lead compound QAV680 and the other CRTh2 antagonists examined in this study. In 
particular QAW039 is significantly slower to dissociate from the CRTh2 receptor (>9 fold 
compared to QAV680) which potentially affords this compound increased efficacy and an 
improved duration of action at the CRTh2 receptor due to sustained blockade of the receptor 
in the face of increasing concentrations of PGD2.  This phenomenon of insurmountability is 
highlighted in the GTPS assay, where QAW039 which exhibits the slowest dissociation rate 
constant, also produced the most pronounced suppression of the maximal response to PGD2 
in the GTPS binding assay.   The slower the compound koff the greater the % inhibition 
achieved in the GTPS binding assay for any given multiple of the compound Ki added. 
QAW039 displays a time-dependent inhibitory effect in the GTPS binding assay its potency 
being highest at early time points (see Figure 8A) characteristic of its slow dissociation from 
the CRTh2 receptor. This may contribute to QAW039’s increased potency in the eosinophil 
whole blood shape change assay relative to the more rapidly dissociating reference 
compounds.  
The detailed pharmacological analysis presented in this study confirms the competitive nature 
of QAW039 and structurally related ligands binding to the human CRTh2 receptor.  In 
particular the observation that the pIC50 for PGD2 displacement of [
3H]-QAW039 binding (to 
the CRTh2 receptor) increased in a linear fashion with equivalent pA2 values at increasing 
radioligand concentration demonstrates that QAW039 behaves as a simple competitive 
antagonist. Similarly PGD2 itself and the two other reference CRTh2 antagonists examined 
OC-459 and AZD-1981 appeared fully competitive with increasing concentrations of 
QAW039 demonstrating that all these molecules occupy the same CRTh2 receptor binding 
pocket. 
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Limited information exists on the MoA of other CRTh2 antagonists, but there are previous 
publications using functional assays that highlight potential insurmountable antagonist 
profiles (Mathiesen et al., 2006; Gervais et al., 2011).   Both publications attribute this 
compound profile to slow receptor dissociation kinetics whereby equilibrium between PGD2 
and receptor is not achieved in the time frame of their experiments.   In contrast, AZD-1981 
has been shown to exhibit a non-competitive binding profile despite possessing rapid 
dissociation kinetics (Schmidt et al., 2013). This was demonstrated using an agonist ([3H]-
PGD2) binding assay and could potentially result from stabilisation of the uncoupled form of 
the CRTh2 receptor. 
In functional studies performed at room temperature and in salt containing buffer QAW039 
behaves as an insurmountable antagonist of PGD2 stimulated GTPS activation following a 
15min agonist equilibration time.  This insurmountable behaviour is entirely consistent with 
QAW039 relatively slow dissociation (t1/2 = 14.4min) from the human CRTh2 receptor but 
does not result from a non-competitive interaction. Thus the time-dependant concentration 
dependent rightward shifts observed with QAW039 in the human GTPs assay coupled with 
the Schild analysis (see Figure 8A and supplemental Figure 3) supports the findings of 
homologous binding studies (see Figure 5) and demonstrates that QAW039 behaves as a 
simple competitive antagonist of PGD2 functional responses. 
To investigate the profile QAW039 at the cellular level, we chose two relevant inflammatory 
cell types.  CRTh2 mediated shape change in eosinophils was used to profile QAW039 in 
whole blood and represents a physiologically relevant environment.  The comparable IC50 
values for QAW039 in the whole blood and isolated shape change assays are consistent with 
its lower plasma protein binding and its relatively slow dissociation kinetics that drive its 
increased potency (see Figure 8A).  Other compounds showed large discrepancies between 
these two assay formats which are likely the result of higher plasma protein binding coupled 
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with rapid dissociation from the CRTh2 receptor.  In the case of QAV680, the reduced 
protein binding does not compensate for the faster dissociation kinetics. These data 
demonstrate that QAW039 is highly potent in whole blood systems with the IC50 value 
obtained being consistent with the affinity values calculated from radioligand experiments.  
In a further disease-relevant cellular context the potency of QAW039 in the isolated Th2 cell 
cytokine inhibition assay, is consistent with its CRTh2 receptor affinity, and as with 
eosinophil assay readouts this represents an improved potency compared to QAV680.  
In summary, in these human functional studies across diverse cellular systems, we have 
determined that the potency of QAW039 is cell type and cell function independent. 
Importantly, the pharmacological profile determined for QAW039 suggests it should 
competitively inhibit other disease relevant CRTh2-mediated responses in human cells 
including Th2 cell cytokine production, PGD2-mediated Th2 cell apoptosis, and basophil 
chemotaxis and eosinophil activation. To our knowledge, this is the first study to demonstrate 
in both binding and functional studies the simple competitive antagonist nature of clinically 
relevant CRTh2 antagonists including the slowly dissociating compound QAW039 and 
represents an important step forward in our understanding of the pharmacology of low 
molecular weight CRTh2 antagonists in competition with their native agonist PGD2.  
QAW039 (fevipiprant) is under ongoing clinical study as a novel oral therapy for allergic 
diseases. 
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Figure legends 
Figure 1.  Structures of the selective CRTh2 antagonist QAW039 and reference CRTh2 
ligands. 
Figure 2.  Characterization of the CRTh2 radioligands [3H]-QAW039 and [3H]-OC-459. 
Saturation binding of [3H]-QAW039 (A) and [3H]-OC-459 (B) to human CRTh2 receptors 
expressed in membranes from CHO cells.  Dissociation of [3H]-QAW039 (C) and [3H]-OC-
459 (D) from human CRTh2 receptors expressed in membranes from CHO cells. Data are 
shown as Mean ± SEM and are representative of three separate experiments performed in 
triplicate. 
Figure 3. Competition binding between [3H]-QAW039 and CRTh2 receptor ligands for 
human CRTh2 receptors expressed in membranes from CHO cells. Displacement of 
[3H]-QAW039 (1 nM) by increasing concentrations of CRTh2 antagonist (A) QAW039, 
QAV680, AZD-1981, OC-459 and BI-671800 and (B) ramatroban and setipiprant plus the 
CRTh2 agonists PGD2 and indomethacin.  Data are presented as the mean range from a 
representative of three experiments performed in duplicate. 
Figure 4. Direct determination of [3H]-QAW039 kinetic binding parameters plus 
competition kinetic binding to determine the kinetic rate constants of unlabeled 
compounds.  (A) Association of [3H]-QAW039 to the human CRTh2 receptor expressed in 
membranes from CHO cells. A family of association kinetic curves was constructed using a 
range of [3H]-QAW039 concentrations. kon and koff values for QAW039 were determined by 
fitting the data to a global kinetic association model. (B) Plot of ligand concentration verses 
kob. Binding followed a simple law of mass action model, kob increasing in a linear manner 
with radioligand concentration.  [3H]-QAW039 competition kinetic curves in the presence of 
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unlabeled QAW039 (A) and OC-459.  CHO-CRTh2 membranes were incubated with ∼2.5 
nM [3H]-QAW039 and the increasing concentrations of unlabeled competitior. Plates were 
incubated at 37°C for the indicated time points and nonspecific binding levels were 
determined in the presence of 3 M AZD-1981. Data were fitted to the equations described in 
Materials and Methods to calculate kon and koff values for the unlabeled ligands; these are 
summarized in Table 2. Data are presented as mean ± range from representative three or more 
experiments performed in duplicate. 
Figure 5.  Determination of the competitive mode of action of QAW039 with PGD2 and 
the selected other CRTh2 antagonists.  Effect of increasing concentrations of [3H]-
QAW039 on the degree of inhibition observed with increasing concentrations of (A) 
QAW039, (B) PGD2, (C) AZD-1981 and (D) OC-459 at human CRTh2 receptors expressed 
in membranes from CHO cells.  (E) Linear increase in the compound pIC50 values with 
increasing [3H]-QAW039 concentrations.  Data are shown as mean ± range and are 
representative of 3 separate experiments performed in duplicate. 
Figure 6.  Effect of CRTh2 antagonists on PGD2 stimulated GTPS accumulation. 
Insurmountable behavior of (A) QAW039 at human CRTh2 receptors expressed in 
membranes from CHO cells following a 15 min incubation period with the agonist PGD2.   
Surmountable behavior of (B) QAV680, (C) AZD-1981, (D) OC-459, (E) BI-671800, (F) 
ramatroban and (G) setipiprant following a 15 min incubation period.  Data are shown as 
mean ± SEM and are representative of 3 separate experiments performed in singlet. 
Figure 7.  Functional consequences of hemi-equilibrium. Effect of CRTh2 antagonists 
acting at human CRTh2 receptors expressed in membranes from CHO cells on % depression 
of a maximally effective concentration of PGD2 (1M) in the [35S]-GTPS assay at the 15min 
time point.  Antagonist potency is expressed as a ratio of concentration added over compound 
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affinity corrected for % HSA bound.  Data are shown as mean ± SEM and are representative 
of 3 separate experiments performed in singlet. 
Figure 8. Effects of hemi-equilibrium on CRTh2 antagonist potency. The effect of time 
on the inhibitory potency of CRTh2 antagonists (A) QAW039, (B) QAV680, (C) AZD-1981, 
(D) OC-459, (E) BI-671800, (F) ramatroban and (G) setipiprant in the [35S]-GTPS binding 
assay following stimulation of the CRTh2 receptor expressed in membranes from CHO cells 
with a maximal effective concentration of PGD2 (1M). Data are shown as mean ± SEM and 
of 3 separate experiments performed in singlet. 
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Tables 
Table 1. Saturation binding and dissociation kinetic rate constant (koff) data for [
3H]-
QAW039 and [3H]-OC-459 binding to human CRTh2 receptors expressed in membranes 
from CHO-cells.  Data are mean ± s.e. mean from at least 3 separate experiments. 
Radioligand Receptor expression 
level (pmol mg-1) 
Dissociation kinetic rate 
constant koff (min
-1) 
Equilibrium 
dissociation constant 
Kd (nM) 
[3H]-QAW039 6.26 ± 0.51 0.050 ± 0.006 1.13 ± 0.44 
[3H]-OC-459 6.44 ± 0.06 2.79 ± 0.53 2.44 ± 0.58 
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Table 2.  Kinetic and equilibrium binding parameters of unlabeled QAW039 and other 
CRTh2 ligands interacting with the human CRTh2 receptor expressed in membranes from 
CHO-cells.   Data are mean ± s.e. mean from at least 3 separate experiments. Nd = not 
determined. 
CRTh2 
ligand 
kon (M
-1min-1) koff (min
-1) t1/2 
(min) 
Kinetic pKd Equilibrium 
pKi 
QAW039 6.27 ± 0.93 x 107 0.061 ± 0.006 12.04 8.99 ± 0.06 8.98 ± 0.03 
QAV680 4.80 ± 2.14 x 107 0.66 ± 0.21 1.29 7.78 ± 0.04 7.54 ± 0.09 
AZD-1981 3.01 ± 0.76 x108 0.77 ± 0.23 1.26 8.57 ± 0.02 8.49 ± 0.03 
OC-459 9.50 ± 5.14 x108 1.83 ± 0.32 0.41 8.48 ± 0.04 8.35 ± 0.13 
BI-671800 2.47 ± 0.36 x108 1.22 ± 0.11 0.58 8.28 ± 0.01 8.14 ± 0.20 
Ramatroban 1.89 ± 0.66 x 107 0.80 ± 0.22 0.80 7.35 ± 0.05 7.45 ± 0.02 
Setipiprant 1.87 ± 0.45 x108 0.95 ± 0.15 0.76 8.28 ± 0.04 8.35 ± 0.06 
PGD2 nd nd nd nd 6.41 ± 0.08 
Indomethacin nd nd nd nd 5.74 ± 0.12 
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Table 3. CRTh2 antagonist human whole blood (WBSC) and isolated cellular (ISC) shape change potency values plus protein binding 
and physicochemical descriptors clogP, logD7.4 and logKIAM .  Data are mean ± SEM for 3 or more experiments. a determined by HPLC 
column method (Kerns et al., 2003) b determined by HPLC column method (Valko et al., 2000) c determined by equilibrium dialysis (Banker et 
al., 2003)  
CRTh2 antagonist clogP log D7.4
a log KIAM7.4
b % human 
plasma protein 
unboundc 
WBSC IC50 (nM) ISC IC50 (nM) 
QAW039 2.26 0.65 1.12 7.8 0.44 ± 0.19 0.40 ± 0.04 
QAV680 1.15 -0.34 0.55 21.4 31.0 ± 1.0 5.0 ± 1.0 
AZD-1981 4.79 1.19 1.77 1.8 13.10 ± 4.03 2.21 ± 0.87 
OC-459 4.57 1.32 1.91 0.5 422.5 ± 155.9 6.4 ± 1.4 
BI-671800 4.58 1.65 1.95 0.4 104.9 ± 35.3 1.87 ± 0.88 
Ramatroban 3.97 1.34 1.89 2.7 195 ± 75.4 11.4 ± 1.9 
Setipiprant 4.28 1.35 1.88 0.4 >500 10.7 ± 1.7 
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Table 4. Comparison of potencies of CRTh2 antagonists QAV680 and QAW039 for 
inhibition of PGD2 induced cytokine release in human CD4+ Th2 lymphocytes. Methods 
described in the supplemental files. Data are mean ± s.e. mean from at least 3 separate 
experiments. 
CRTh2 antagonist Inhibition of IL-5 release IC50 
(nM) 
Inhibition of IL-13 release IC50 
(nM) 
QAW039 2.56 ± 1.24 1.40 ± 0.30 
QAV680 57 ± 28 29 ± 5 
 
